Dr. Daver Discusses Use of MRD Assessment in Hematologic Malignancies

Name: Dr. Daver Discusses Use of MRD Assessment in Hematologic Malignancies
Uploaded: 2019-03-02T01:03:00.000Z
Description: Naval G. Daver, MD, discusses the role of minimal residual disease assessment in the treatment of patients with hematologic malignancies.

March 1, 2019

Naval G. Daver, MD

Video

Conference|PER® Congress on Hematologic Malignancies (Winter Hematology®)

Naval G. Daver, MD, discusses the role of minimal residual disease assessment in the treatment of patients with hematologic malignancies.

Naval G. Daver, MD, oncologist, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the role of minimal residual disease (MRD) assessment in the treatment of patients with hematologic malignancies. Daver says MRD has emerged as an important part of predicting outcomes in these patients compared to previous standards in this setting.